LG Life Sciences Ltd (formerly LG Chem Ltd), in collaboration with Anadys Pharmaceuticals Inc, is developing LB-80380 (PMCDG dipivoxil), an orally available lead compound in a series of phosphonate nucleotides, for the potential treatment of hepatitis B virus infection. In April 2003, phase II trials were initiated, the results of which were reported in February 2006. LB-80380 is the prodrug of LB-80317 (PMCDG), another compound from this series.

中文翻译：

---

药物评估：LB-80380-一种可潜在治疗HBV感染的新型膦酸核苷。

LG生命科学有限公司（以前的LG Chem Ltd）与Anadys Pharmaceuticals Inc.合作，正在开发LB-80380（PMCDG dipivoxil），它是一系列膦酸酯核苷酸中的口服铅化合物，可用于治疗乙型肝炎病毒感染。2003年4月，开始进行II期试验，其结果于2006年2月报告。LB-80380是LB-80317（PMCDG）的前药，是该系列的另一种化合物。